Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer-Reference-Cited by-同舟云学术

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

Published:2019-01-01 Issue:1 Volume:5 Page:74
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Emens Leisha A.¹²,Cruz Cristina³,Eder Joseph Paul⁴,Braiteh Fadi⁵,Chung Cathie⁶,Tolaney Sara M.⁷,Kuter Irene⁸,Nanda Rita⁹,Cassier Philippe A.¹⁰,Delord Jean-Pierre¹¹,Gordon Michael S.¹²,ElGabry Ehab¹³,Chang Ching-Wei¹⁴,Sarkar Indrani¹⁵,Grossman William¹⁴¹⁵,O’Hear Carol¹⁴,Fassò Marcella¹⁴,Molinero Luciana¹⁴,Schmid Peter¹⁶

Affiliation:

1. Bloomberg-Kimmel Institute for Cancer Immunotherapy, Department of Oncology, Johns Hopkins University, Baltimore, Maryland

2. now with Department of Medicine and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh

3. Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain

4. Department of Medicine (Oncology), Yale Cancer Center, New Haven, Connecticut

5. Comprehensive Cancer Centers of Nevada, University of Nevada Las Vegas School of Medicine, Las Vegas

6. The Angeles Clinic and Research Institute, Los Angeles, California

7. Department of Medicine,Dana-Farber Cancer Institute, Boston, Massachusetts

8. Department of Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston

9. Section of Hematology/Oncology, University of Chicago, Chicago, Illinois

10. Department of Medical Oncology, Centre Léon-Bérard, Lyon, France

11. Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France

12. HonorHealth Research Institute, Scottsdale, Arizona

13. Ventana Medical Systems, Inc, Tucson, Arizona

14. Genentech, Inc, South San Francisco, California

15. now with Bellicum Pharmaceuticals, Inc, South San Francisco, California

16. Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, England

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference37 articles.

1. Triple-negative breast cancer: an unmet medical need.;Hudis;Oncologist,2011

2. Triple negative breast cancer—an overview.;Aysola;Hereditary Genet,2013

3. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.;Li;Breast Cancer Res Treat,2017

4. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.;den Brok;Breast Cancer Res Treat,2017

5. Current approaches in treatment of triple-negative breast cancer.;Wahba;Cancer Biol Med,2015

Cited by 540 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial;Nature Communications;2024-02-03

2. Expression of programmed death-ligand 1, IRF1 and CD8 T lymphocyte infiltration in a primary subset of breast cancer patients in Sudan;Journal of Taibah University Medical Sciences;2024-02

3. Pan-cancer analysis of 60S Ribosomal Protein L7-Like 1 (RPL7L1) and validation in liver hepatocellular carcinoma;Translational Oncology;2024-02

4. PD-L1 Expression and Silva Invasion Pattern in Villoglandular Adenocarcinoma of the Uterine Cervix;International Journal of Gynecological Pathology;2024-01-31

5. High CTLA-4 gene expression is an independent good prognosis factor in breast cancer patients, especially in the HER2-enriched subtype;2024-01-31